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Antimicrobial agents secreted into urine potentially play a powerful role in the defense of the urinary tract. In
this issue of Immunity, Jaillon et al. (2014) describe a role for pentraxin 3 molecules in complementing the
host’s cellular innate immune responses to uropathogens.The urinary tract, which comprises the
kidneys, ureters, bladder, and urethra,
serves as the body’s drainage system
for removing wastes and extra water.
Despite its close proximity to the gastroin-
testinal tract, where trillions of microbes
are harbored, the urinary tract, for the
most part, appears sterile. The resistance
to infection of the urinary tract is partially
ascribable to its unique anatomy and
to the flushing action of urine and uri-
nary mucins, which rapidly eliminate any
contaminating bacteria (Chromek and
Brauner, 2008). In addition, the urinary
tract constitutively produces antimicro-
bial agents such as Cathelicidins that
directly kill pathogens (Chromek et al.,
2006). Tamm-Horsfall protein (THP), also
known as uromodulin, is another constitu-
ent of urine secreted by the kidneys,
which serves to aggregate various bacte-
ria, facilitating their early removal by urine
(Sa¨emann et al., 2005).
Prospective uropathogens that resist
these attempts at clearance are then
challenged by the innate immune system
of the urinary tract. The bladder epithe-
lium is richly endowed with immunosen-
sory molecules, such as Toll-like receptor
4 (TLR4), which upon activation promptly
initiates a broad spectrum of antibacterial
responses (Schilling et al., 2003). These
responses include local secretion of
several proinflammatory cytokines and
chemokines, which is accompanied by a
rapid neutrophil response. In this issue
of Immunity, Jaillon et al. (2014) report
that complementing these cellular innate
responses in the urinary tract is a humoral
arm of the innate immune responses
comprising of secretion into the urine of
a soluble pattern recognition molecule,
pentraxin 3 (PTX3). These authors report460 Immunity 40, April 17, 2014 ª2014 Elsevthat PTX3 secretion in urine was mark-
edly enhanced in humans and mice after
UTIs and that mice deficient in PTX3
were found to be highly impaired in their
capacity to clear uropathogenic Escheri-
chia coli after vesicular challenge. PTX3
appears to be the first humoral pattern
recognition molecule implicated in innate
immune defense against UTIs.
Pentraxins are a superfamily of evolu-
tionarily conserved secreted proteins,
which contain an 8 amino acid-long pen-
traxin signature in the C terminus pen-
traxin domain (Bottazzi et al., 2010).
Different pentraxins are able to bind
distinct microbial pattern molecules,
such as lipopolysacchrides (LPS), lipo-
proteins, and outer membrane proteins
(Omp). Binding of soluble pentraxins to
their corresponding ligands on microbes
triggers complement-mediated killing or
direct pathogen neutralization or pro-
motes the opsonization and uptake of
the pathogen by phagocytic cells (Bot-
tazzi et al., 2010). PTX3 is a prominent
member of the pentraxin family that has
been reported to play a protective role
against several bacterial and fungal path-
ogens (Garlanda et al., 2002), but their
contribution to the clearance of uropatho-
gens have not previously been examined.
Jaillon et al. (2014) observed that PTX3
levels locally (in the urine) as well as in the
blood were markedly enhanced after in-
travesicular challenge of wild-type mice
with uropathogenic E. coli (UPEC). The
functional significance of PTX3 produc-
tion in the urinary tract was deduced by
comparing bacterial burden in the bladder
and kidneys of wild-type and Ptx3-
deficient mice after UPEC challenge. The
bacterial burden was significantly higher
in Ptx3/ mice compared to wild-typeier Inc.mice, and this difference paralleled the
number of macroscopic abscesses in
the kidneys of the two groups of mice.
Compared to infected wild-type mice,
infected Ptx3/ mice experienced early
and persistent exacerbated inflammation,
accompanied by markedly more severe
loss in the body weight. Interestingly, the
primary sources of PTX3 in the urinary
tract were the epithelial cells lining the kid-
neys and the bladder as well as the large
population of leukocytes recruited into
the urinary tract after infection. Studies
undertaken in vitro via uroepithelial cell
lines indicated that the TLR4-MyD88
signaling axis on these cells was respon-
sible for promoting the PTX3 response
to bacterial infection. The authors next
investigated how PTX3 proteins pro-
moted bacterial clearance in the urinary
tract. They observed that PTX3 served
as opsonins, directly binding UPEC
and promoting uptake by neutrophils
(Figure 1). To explain the increased clear-
ance of bacteria in the urinary tract of
wild-type mice, the authors showed that
the phagosomes of wild-type neutrophils
containing PTX3-coated UPEC matured
at faster rates than in phagocytes bearing
uncoated UPEC, suggesting that PTX3
promoted increased intracellular killing
of UPEC by neutrophils. Clinical evidence
supporting a role for PTX3 in immunity in
the urinary tract comes from the findings
that PTX3 levels in the urine were mark-
edly higher in UTI patients than in the urine
of healthy donors or patients with other
types of infections. There even appeared
to be significant differences in PTX3
levels in the urine of UTI patients with
varying severity: PTX3 levels in patients
with acute pyelonephritis (APN) were
significantly higher than in cystitis patients
Figure 1. PTX3 Functions as an Opsonin Promoting UPEC Uptake by Neutrophils
Invading uropathogenic E. coli are sensed by TLR4 molecules lining the surface of the superficial epithe-
lium of the urinary tract. The activation of TLR4 leads to the production and secretion of PTX3 via the
MyD88 signaling cascade, probably by translocation of the downstream NF-kB transcription factor into
the nucleus. Secreted PTX3 binds bacteria in the urine, promoting their uptake into neutrophil phago-
somes that rapidly mature because of the presence of PTX3, and culminating in early clearance of the
bacteria.
Immunity
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uria. Consistent with recent reports linking
genetic polymorphisms in the PTX3 locus
to both the production of PTX3 in different
individuals and their corresponding sus-
ceptibility to fungal infections (Cunha
et al., 2014), Jaillon et al. (2014) found
that PTX3 polymorphisms were associ-
ated with susceptibility to acute pyelone-
phritis. Thus, there appears to be multiple
lines of evidence pointing to PTX3 as be-
ing an essential component of the innate
immune network of the urinary tract.
That urine is a rich growth medium for
bacterial growth has been widely recog-
nized since 1863 when Louis Pasteur
was credited withmaking this observation
(Asscher et al., 1966). Urine is usually
retained in the bladder for hours, so the
bladder represents a powerful incubator
for bacterial growth. Bacterial numbers
in the bladder can actually reach levels
in excess of 108 per ml. Indeed, 1 3 105
per ml of urine is the critical number
traditionally employed in clinical labora-
tory to differentiate between infection
and contamination. Controlling the high
numbers of bacteria attained in the urine
represents a significant challenge to the
urinary tract. One counter measure em-
ployed by the host’s immune defenses
is secretion into the urine of fluid-phase
pattern recognitions molecules (PRMs).These molecules can directly bind and
aggregate bacteria in the urine so that
they either are unable to attach to bladder
walls or are internalized and killed in
greater numbers by immune cells. Until
now, most of the fluid-phase PRMs in
urine were thought to be constitutively
produced (e.g., THP). Although these
ready-made components could be highly
effective in eliminating the occasional
intruder into the lower urinary tract, their
amounts are not sufficient to eliminate
bacteria that have already begun to
multiply in great numbers in the urine.
The current study by Jaillon et al. (2014)
reveals that the urinary tract has in reserve
another family of fluid-phase PRMs that
are actively induced and secreted in
direct proportion to the size of the micro-
bial challenge and which is triggered
by the LPS-sensing immune surveillance
molecule TLR4.
Although compelling and informative,
this study also raises many questions.
For example, it is not known how phago-
somes encasing PTX3-opsonized UPEC
are induced to rapidly mature, leading
to the demise of its microbial cargo. The
impact of PTX3 on bacterial numbers in
the infected mouse bladder and kidneys
is very striking. Although the authors
have shown with in vitro supporting data
that PTX3 promotes bacterial clearanceImmunityby acting as an opsonin, it may not be
the whole story. First, little difference
in bacterial clearance between wild-type
and Ptx3/ mice was observed on day
1 in the bladder when neutrophil numbers
in the urinary tract was possibly at its
highest level. Indeed, significant differ-
ences in bacterial numbers in the blad-
ders and kidneys in the two groups of
mice were mostly seen on day 5. Second,
although neutrophils are highly effective
in bacterial clearance, it is unclear how
effective they will be in the urinary tract
because pH, osmolality, and toxins
in the urine may negatively impact their
phagocytic and bactericidal activities.
Thus, this study may represent just the
tip of the iceberg with regard to PTX3’s
protective role in the urinary tract. There
are emerging data suggesting that
pentraxins play a key role in modu-
lating various arms of the inflammatory
response and that PTX3may have several
cellular targets (Soares et al., 2006). With
the finding that most of the protective ac-
tions of PTX3 are evident only by the fifth
day of infection, there is also a possibility
that PTX3 may be achieving its effects
via the adaptive immune system. Thus,
although PTX3 has a significant protective
role in the urinary tract, its mode of action
might be multifaceted.
Urine volume and composition has
often been employed as a barometer of
the physiological state of the host. Jaillon
et al. (2014) have shown the value of
interrogating urine samples in revealing
novel components of the innate immune
response. Interestingly, they have also
reported that there appears to be a direct
correlation between PTX3 levels in the
urine and the magnitude of infection,
raising the possibility of utilizing PTX3
as a biomarker for UTIs, which could be
a valuable adjunct to current diagnostic
approaches.REFERENCES
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